XpertRCM’s Post

I'm not sure if this is what we were waiting for: Per an FDA document, treatment-emergent adverse events (TEAEs) were reported by 89% of donanemab-treated patients. The most common AEs were amyloid-related imaging abnormalities (ARIA)–edema/effusions (ARIA-E; 24%), ARIA-hemorrhage/hemosiderin deposition (ARIA-H; 18%), COVID-19 (14%), fall (13%), and headache (13%). Serious AEs were reported by 17% of donanemab-treated patients. To make it worse, in TRAILBLAZER-ALZ clinical trial, 27.5 % experienced ARIA-E and 30.5% of donanemab patients had ARIA-H. Alzheimer's Association should not wait to recommend interventions. Plenty of nonpharmaceutical interventions have been proven to be significantly more effective than Donanemab in well-designed clinical trials. Some even reversed the cognitive decline.

I'm not sure if this is what we were waiting for: Per an FDA document, treatment-emergent adverse events (TEAEs) were reported by 89% of donanemab-treated patients. The most common AEs were amyloid-related imaging abnormalities (ARIA)–edema/effusions (ARIA-E; 24%), ARIA-hemorrhage/hemosiderin deposition (ARIA-H; 18%), COVID-19 (14%), fall (13%), and headache (13%). Serious AEs were reported by 17% of donanemab-treated patients. To make it worse, in TRAILBLAZER-ALZ clinical trial, 27.5 % experienced ARIA-E and 30.5% of donanemab patients had ARIA-H. Alzheimer's Association should not wait to recommend interventions. Plenty of nonpharmaceutical interventions have been proven to be significantly more effective than Donanemab in well-designed clinical trials. Some even reversed the cognitive decline.

Step by Step

Breaking News: The FDA has granted approval of Kisunla (donanemab) for the treatment of people living with early symptomatic Alzheimer’s disease. Early symptomatic Alzheimer’s disease significantly impacts individuals by marking the onset of cognitive decline, which can affect daily functioning and independence. Early diagnosis and intervention, as highlighted by the FDA's approval of treatments like Kisunla (donanemab), aim to slow this decline, offering individuals more time and potentially better quality of life. #unitedseniorassociation #USA #eldercare #FDA #NCON #seniorliving #ADA #AI #NIH #patientcare #compliance #hospitals #OIG #healthcare #HHSOIG #digitalhealth #HSS #CMS #assistedliving #AMA #NCN #nursinghomes #seniorcare #medicare #seniorcitizen #homehealthcare #caregiver #dementia #inhomecare #seniorhealth #kloekorby #alzheimers #mentalhealth

The latest advancements in treatment and prevention are so hopeful. 💜

Results from a recent clinical trial show promise for semaglutide as a treatment to help slow progression of kidney disease & reduce the risk of death for those living with diabetic kidney disease. Learn more about semaglutide: bit.ly/3J3t0CN

November is Crohn's and Colitis Awareness Month. More than 10 million people live with Crohn's Disease or Ulcerative Colitis, also known as Inflammatory Bowel Disease (IBD). As a leader in infusion care, VItal Care offers several treatments, including Stelara and Entyvio, to help with Crohn's and Colitis. #infusiontherapy #specialtypharmacy #stelara #ivinfusion #infusions #infusion #crohnsdisease #InfusionPharmacy #pharmacy #ulcerativecolitis #plaquepsoriasis #psoriaticarthritis #psoriasis #vitalcare

November is Crohn's and Colitis Awareness Month. More than 10 million people live with Crohn's Disease or Ulcerative Colitis, also known as Inflammatory Bowel Disease (IBD). As a leader in infusion care, VItal Care offers several treatments, including Stelara and Entyvio, to help with Crohn's and Colitis. #infusiontherapy #specialtypharmacy #stelara #ivinfusion #infusions #infusion #crohnsdisease #InfusionPharmacy #pharmacy #ulcerativecolitis #plaquepsoriasis #psoriaticarthritis #psoriasis #vitalcare

We have data demonstrating GLP1 benefit in diabetic kidney disease, but what about non-diabetic kidney disease? 🤔 Enter the SMART trial which enrolled adults with BMI >27 and non-diabetic CKD and randomized to semaglutide vs. placebo Baseline BMI 36, GFR 65, urine albumin to creatinine (UACR) ratio 251 ⬇️51% reduction in UACR in semaglutuide by week 24 https://lnkd.in/eHhiiQT5

When it comes to rheumatoid arthritis (RA), here's a clinical tip that can help you to get at the roots of your patients’ suffering. - Do you know the infectious dynamics most often involved in RA? Are you aware of the everyday lab marker that can help you uncover the gut dysfunction common in RA cases? - And what could the gallbladder possibly have to do with this debilitating joint disease? Discover these functional insights and more in our Clinical Tip Blog: https://lnkd.in/guebZNhy. #TipTuesday #FxMed #SAFM #PreventiveHealthcare #RootCauseResolution #RootCauseHealing #HealthCareTransformation #LifestyleMedicine #HolisticMedicine #FunctionalMedicine #FunctionalMedicinePractitioner